Acalabrutinib market is witnessing strong growth momentum driven by recent regulatory approvals and expanding use in combination regimens for hematologic malignancies. In February 2026, the U.S. Food and Drug Administration approved acalabrutinib (marketed as Calquence by AstraZeneca) in combination with Venetoclax (Venclexta) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This approval marks a significant advancement in first-line treatment options for patients with these blood cancers.
The approval was supported by data from the Phase 3 AMPLIFY trial, which demonstrated a statistically significant improvement in progression-free survival (PFS) compared to standard chemoimmunotherapy regimens. The combination therapy showed a hazard ratio of 0.65, indicating a 35% reduction in disease progression or death risk versus comparator treatments such as fludarabine-based or bendamustine-based regimens. Additionally, lower mortality rates were observed in the acalabrutinib plus venetoclax arm, reinforcing its clinical benefit in untreated CLL patients.
Further strengthening its market position, acalabrutinib received FDA approval in January 2025 for use in combination with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation. This approval was based on results from the Phase 3 ECHO trial, which demonstrated a significant improvement in PFS, with median survival extending to over 66 months in the combination arm compared to approximately 49 months in the control group. In addition, acalabrutinib also secured full approval as a monotherapy for previously treated MCL, converting its earlier accelerated approval granted in 2017.
From a safety standpoint, acalabrutinib carries warnings related to infections, bleeding, cardiac arrhythmias, and cytopenias, while venetoclax is associated with risks such as tumor lysis syndrome and neutropenia. Despite these risks, the overall benefit-risk profile remains favorable in indicated populations.
Overall, the acalabrutinib market is evolving toward combination-based, chemotherapy-free treatment approaches, reflecting a broader shift in oncology toward targeted therapies. These recent FDA approvals are expected to drive increased adoption, enhance treatment outcomes, and strengthen acalabrutinib’s position as a key therapy in the management of hematological cancers.
